Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
Eli Lilly in Talks to Acquire Kelonia Therapeutics for Over $2 Billion 
Nidec Stock Rises After Accounting Probe Report Eases Delisting Concerns 
Amazon Expands AI Bet with Up to $25 Billion Investment in Anthropic 
Jeff Bezos Eyes $10 Billion Funding Round for AI Venture Project Prometheus 
John Ternus Signals Apple’s Future with Product-First AI Strategy 
Tesla Q1 Earnings Preview: Robotaxi Delays and SpaceX Merger Speculation Grow 
JAPEX Shares Drop as Middle East Tensions Drive LNG Costs and Production Risks 
Australia Extends Fuel Sulphur Relaxation Amid Iran War Supply Disruptions 
Polymarket Seeks $400M Funding Round, Targets $15B Valuation Amid Prediction Market Boom 
Apple Stock Dips as Tim Cook Steps Down, John Ternus Named Next CEO 
AEVEX Raises $320 Million in IPO Amid Surging Defense Sector Demand 
Apple Wins ITC Ruling, Keeping Blood-Oxygen Feature on Apple Watch 
Chinese Robotics Stocks React as Humanoid Robot Marathon Sparks Competition Concerns 
How Technology Is Reshaping Modern Business: From Operations to Customer Experience 
China Food Delivery Stocks Dip as Regulators Crack Down on “Ghost Deliveries” 
Indian Refiners Use Yuan via ICICI Bank to Pay for Iranian Oil Under U.S. Sanctions Waiver 
EMERYVILLE, Calif., March 02, 2017 -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS) disorders, today announced that it will report its financial results for the fourth quarter and full-year ended December 31, 2016, after the market close, and will host a corporate update conference call and webcast on Thursday, March 9th, at 4:30 PM Eastern Time.
| Thursday, March 9th @ 4:30 PM Eastern Time/1:30 PM Pacific Time | |
| Toll Free: | 877-675-4750 |
| International: | 719-325-4867 |
| Conference ID: | 1061121 |
| Webcast: | http://public.viavid.com/index.php?id=122985 |
| Replays, available through March 23, 2017: | |
| Domestic: | 844-512-2921 |
| International: | 412-317-6671 |
| Replay PIN: | 1061121 |
About Zogenix
Zogenix, Inc. (Nasdaq:ZGNX) is a pharmaceutical company committed to developing and commercializing CNS therapies that address specific clinical needs for people living with orphan and other CNS disorders who need innovative treatment alternatives to improve their daily functioning.
For more information, visit www.zogenix.com.
CONTACT: Investors: Andrew McDonald Founding Partner, LifeSci Advisors LLC 646-597-6987 | [email protected]
